Tag Archives: NASDAQ:OREX

Healthcare Sector Quick Roundup: Quest Diagnostics (NYSE:DGX), Synta Pharmaceuticals (NASDAQ:SNTA) – DGX, SNTA, PFE, CHDX, FLML, OREX

Posted on March 15, 2013 by Thomas Vedder

Thursday’s trading session data confirmed that healthcare sector finished positively with +0.34% change. Chindex International, Inc (NASDAQ:CHDX) and Flamel Technologies SA (ADR) (NASDAQ:FLML) were major percentage gainers in this sector while key percentage decliner was Orexigen Therapeutics, Inc (NASDAQ:OREX).

Quest …

Posted in Healthcare, Latest Headlines | Tagged CHDX, Chindex International, DGX, Flamel Technologies, FLML, NASDAQ:CHDX, NASDAQ:FLML, NASDAQ:OREX, NASDAQ:SNTA, NYSE:DGX, NYSE:PFE, OREX, Orexigen Therapeutics, PFE, Pfizer, Quest Diagnostics, SNTA, Synta Pharmaceuticals | Comments Off

Healthcare Stocks In focus; Gilead (GILD) Board Approve 2-for-1 Stock Split while Peregrine Pharmaceuticals (PPHM) Posts Narrower Loss inQ2 – GILD, PPHM, PFE, INFI, OREX, JNJ

Posted on December 11, 2012 by Thomas Vedder

Investors reacted positively to the healthcare stocks on Monday. Key movement were seen in Infinity Pharmaceuticals Inc (NASDAQ:INFI) and Orexigen Therapeutics, Inc (NASDAQ:OREX) on percentage gainers side while Johnson & Johnson (NYSE:JNJ) was prominent stock on most active side.

Gilead …

Posted in Healthcare, Latest Headlines | Tagged GILD, Gilead Sciences, INFI, Infinity Pharmaceuticals, JNJ, Johnson, NASDAQ:GILD, NASDAQ:INFI, NASDAQ:OREX, NASDAQ:PPHM, NYSE:JNJ, NYSE:PFE, OREX, Orexigen Therapeutics, Peregrine Pharmaceuticals, PFE, Pfizer, PPHM | Comments Off

Orexigen Therapeutics (OREX) Offering Stock and Debt Blended Securities – OREX, ABT, GSK, UNH, THC, GILD, PFE, MRK, JNJ

Posted on September 17, 2012 by Geoff Noir

Orexigen Therapeutics Inc. (NASDAQ:OREX) filed initiatives to offer almost $150 million in mixed securities, comprising of stock and debt.

Orexigen shares tumbled 4.3% in extended trading session to $5.32. Through the ending, the stock had increased three times above its …

Posted in Latest Headlines, Services | Tagged Abbott Laboratories, ABT, GILD, Gilead Sciences, GlaxoSmithKline, GSK, JNJ, Johnson, Merck, MRK, NASDAQ:GILD, NASDAQ:OREX, NYSE:ABT, NYSE:GSK, NYSE:JNJ, NYSE:MRK, NYSE:PFE, NYSE:THC, NYSE:UNH, OREX, Orexigen Therapeutics, PFE, Pfizer, Tenet Healthcare, THC, UNH, UnitedHealth | Comments Off

Healthcare Stocks Soars as Cooper Companies (NYSE:COO) Profit Soars 51% While Accuray (NASDAQ:ARAY) Declares a Net Loss in Fourth Quarter – COO, ARAY, VAR, OREX, BDSI, WCRX

Posted on September 7, 2012 by Geoff Noir

Investors reacted positively to the Healthcare stocks on Thursday. Major movement was seen in Orexigen Therapeutics, Inc (NASDAQ:OREX) and BioDelivery Sciences International, Inc (NASDAQ:BDSI) on gainers side while Warner Chilcott Plc (NASDAQ:WCRX) was prominent stock on the losers side.

The …

Posted in Healthcare, Latest Headlines | Tagged Accuray, ARAY, BDSI, BioDelivery Sciences, COO, Cooper, NASDAQ:ARAY, NASDAQ:BDSI, NASDAQ:OREX, NASDAQ:WCRX, NYSE:COO, NYSE:VAR, OREX, Orexigen Therapeutics, VAR, Varian Medical, Warner Chilcott, WCRX | Comments Off

Arena Pharmaceuticals (NASDAQ:ARNA) Declares Net Loss in the Second Quarter – ARNA, VVUS, OREX, GSK

Posted on August 10, 2012 by Thomas Vedder

Arena Pharmaceuticals, Inc (NASDAQ:ARNA) announced a net loss in the second-quarter allocable to common stockholders of $22.1 million or $0.12 a share, narrower than $22.9 million or $0.16 a share in same period previous year.

The company reported that total …

Posted in Healthcare, Latest Headlines | Tagged Arena Pharmaceuticals, ARNA, GlaxoSmithKline, GSK, NASDAQ:ARNA, NASDAQ:OREX, NASDAQ:VVUS, NYSE:GSK, OREX, Orexigen Therapeutics, Vivus, VVUS | Comments Off

Johnson & Johnson (JNJ) Lowers 2012 Guidance; Profit Smashed by Currency Rates

Posted on July 17, 2012 by Thomas Vedder

Johnson & Johnson (NYSE:JNJ), the world’s largest manufacturer of health-care items, trimmed its full-year profit estimation on critical foreign-exchange rates.

J&J’s 2Q net income declined almost 49 percent to $1.4 billion, or 50 cents per share, on takeover expense, …

Posted in Healthcare, Latest Headlines | Tagged Anthera, Arena Pharmaceuticals, Covidien, JNJ, Johnson & Johnson, NASDAQ:ANTH, NASDAQ:ARNA, NASDAQ:OREX, NASDAQ:SLTM, NASDAQ:STEM, NASDAQ:VVUS, Novartis AG, NYSE:COV, NYSE:JNJ, NYSE:NVS, Orexigen Therapeutics, Solta Medical, StemCells, Vivus | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.